Neurocrine Biosciences has launched a Phase 2 clinical trial for NBI-1117567 (NBI-'567), an oral drug targeting muscarinic receptors to improve cognition in adults with mild to moderate Alzheimer's disease. The study will test the drug's efficacy and safety over 12 weeks in about 135 patients already on acetylcholinesterase inhibitors. This trial aims to address cognitive decline by activating brain receptors linked to memory and learning, potentially offering a new treatment option for Alzheimer's patients. Results will clarify NBI-'567's role in managing cognitive symptoms alongside existing therapies.
As of Oct 20, 2026 19:41 WIB, Neurocrine Biosciences Inc (NBIX) shares are trading at USD 137.56 on Pluang, showing a modest 0.42% increase in the last day. Despite this slight rise, the platform's order activity is currently 100% Sell, indicating strong selling interest among investors. The company's market capitalization stands at $13.93 billion, reflecting its significant presence in the health sector.
